Dose-specific efficacy of Haemophilus influenzae type b conjugate vaccines: A systematic review and meta- Analysis of controlled clinical trials

Epidemiology and Infection

Volumn 140, Issue 8, 2012, Pages 1343-1355

  Griffiths, U K ^a   Clark, A ^a   Gessner, B ^b   Miners, A ^a   Sanderson, C ^a   Sedyaningsih, E R ^c   Mulholland, K E ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b Agence de Medecine Preventive   (France)

^c MINISTRY OF HEALTH   (Indonesia)

Author keywords

Efficacy; Haemophilus influenzae; meta Analysis; systematic review; vaccine

Indexed keywords

HAEMOPHILUS INFLUENZAE TYPE B VACCINE; PLACEBO;

BACTERIAL PNEUMONIA; CONTROLLED CLINICAL TRIAL (TOPIC); DOSE RESPONSE; DRUG EFFICACY; HAEMOPHILUS INFECTION; HAEMOPHILUS MENINGITIS; HOSPITAL INFECTION; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; VACCINATION;

DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; HAEMOPHILUS VACCINES; HUMANS; IMMUNIZATION SCHEDULE; VACCINES, CONJUGATE;

EID: 84863979683     PISSN: 09502688     EISSN: 14694409     Source Type: Journal    
DOI: 10.1017/S0950268812000957     Document Type: Review

References (45)

1. Peltola H. Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use ofthe polysaccharide vaccine and a decade after the advent of conjugates. Clinical Microbiology Reviews 2000; 13: 302-317.
2. WHO. Vaccine-preventable disease monitoring system. Global and regional immunization profile (http:// wwwwhoint/immunization-monitoring/en/globalsum mary/GS-GLOProfilepdf). Accessed December 2011.
3. Zuber PL, et al. Sustaining GAVI-supported vaccine introductions in resource-poor countries. Vaccine 2011; 29: 3149-3154.
4. Kelly DF, Moxon ER, Pollard AJ. Haemophilus influenzae type b conjugate vaccines. Immunology 2004; 113: 163-174.
5. Eskola J, et al. A randomized, prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive Haemophilus influenzae type b disease. New England Journal of Medicine 1990; 323: 1381-1387.
6. Ward J, et al. Limited efficacy of a Haemophilus influenzae type b conjugate vaccine in Alaska Native infants. The Alaska H. influenzae Vaccine Study Group. New England Journal of Medicine 1990; 323: 1393-1401.
7. WHO. WHO Position Paper on Haemophilus influenzae type b conjugate vaccines Weekly Epidemiological Record 2006; 81: 445-452.
8. Capeding MR, et al. The immunogenicity of three Haemophilus influenzae type B conjugate vaccines after a primary vaccination series in Philippine infants. American Journal of Tropical Medicine and Hygiene 1996; 55: 516-520.25.
9. Clemens J, et al. Evaluating new vaccines for developing countries. Efficacy or effectiveness? Journal of American Medical Association 1996; 275: 390-397.
10. Griffiths UK, Miners A. Economic evaluations of Haemophilus influenzae type b vaccine: systematic review of the literature. Expert Review of Pharmacoecononics and Outcomes Research 2009; 9: 333-346.
11. Clark A, Sanderson C. Timing of children's vaccinations in 45 low-income and middle income countries: an analysis of survey data. Lancet 2009; 373: 1543-1549.
12. Fitzwater SP, et al. Haemophilus influenzae type b conjugate vaccines: considerations for vaccination schedules and implications for developing countries. Human Vaccines 2010; 6: 810-818.
13. Obonyo CO, Lau J. Efficacy of Haemophilus influenzae type b vaccination of children: a meta- Analysis. European Journal of Clinical Microbiology and Infectious Diseases 2006; 25: 90-97.
14. O'Loughlin RE, et al. Methodology and measurement of the effectiveness of Haemophilus influenzae type b vaccine: systematic review. Vaccine 2010; 28: 6128-6136.
15. Liberati A, et al. The PRISMA statement for reporting systematic reviews and meta- Analyses of studies that evaluate health care interventions : explanation and elaboration. PLoS Medicine 2009; 6: e1000100.
16. Dickersin K, et al. Development of the Cochrane Collaboration's CENTRAL Register of controlled clinical trials. Evaluation & the Health Professions 2002; 25: 38-64.
17. Higgins JPT, Green, S (eds). Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, March 2011.
18. Cherian T. Describing the epidemiology and aetiology of bacterial pneumonia in children: an unresolved problem. Journal of Health Population and Nutrition 2005; 23: 1-5.
19. Shann F. Determining etiology of pneumonia. Pediatric Infectious Disease Journal 1995; 14: 920-921.
20. Obaro SK, Madhi SA. Bacterial pneumonia vaccines and childhood pneumonia: are we winning, refining, or redefining? Lancet Infectious Diseases 2006; 6: 150-161.
21. Mulholland K, et al. Randomised trial of Haemophilus influenzae type-b tetanus protein conjugate for prevention of pneumonia and meningitis in Gambian infants. Lancet 1997; 349: 1191-1197.
22. Deeks JJ, Altman, DG, Bradburn, MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta- Analysis. In: Egger, M, Smith, GD, Altman, DG, eds. Systematic Reviews in Health Care Meta- Analysis in Context: BMJ Books, 2001.
23. Higgins JP, et al. Measuring inconsistency in metaanalyses. British Medical Journal 2003; 327: 557-560.
24. Peltola H, et al. Clinical comparison of the Haemophilus influenzae type B polysaccharide diphtheria toxoid and the oligosaccharide-CRM197 protein vaccines in infancy. Archives of Pediatrics & Adolescent Medicine 1994; 148: 620-625.
25. Santosham M, et al. The efficacy in Navajo infants of conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outermembrane protein complex. New England Journal of Medicine 1991; 25: 1767-1772.
26. Gessner BD. Haemophilus influenzae type b vaccine impact in resource-poor settings in Asia and Africa. Expert Review Vaccines 2009; 8: 91-102.
27. Gessner BD, et al. Incidences of vaccine-preventable Haemophilus influenzae type b pneumonia and meningitis in Indonesian children: hamlet-randomised vaccine- probe trial. Lancet 2005; 365: 43-52.
28. Theodoratou E, et al. The effect of Haemophilus influenzae type b and pneumococcal conjugate vaccines on childhood pneumonia incidence, severe morbidity and mortality. International Journal of Epidemiology 2010; 39 (Suppl. 1): i172-185.
29. Baqui AH, et al. Effectiveness of Haemophilus influenzae type b conjugate vaccine on prevention of pneumonia and meningitis in Bangladeshi children: a case-control study. Paediatric Infectious Disease Journal 2007; 26: 565-571.
30. Ward JI, et al. Invasive Haemophilus influenzae type b disease in Alaska: background epidemiology for a vaccine efficacy trial. Journal of Infectious Diseases 1986; 153: 17-26.
31. Singleton R, et al. The Alaska Haemophilus influenzae type b experience: lessons in controlling a vaccinepreventable disease. Pediatrics 2006; 118: e421-429.
32. Cowgill KD, et al. Effectiveness of Haemophilus influenzae type b conjugate vaccine introduction into routine childhood immunization in Kenya. Journal of American Medical Association 2006; 296: 671-678.
33. Lagos R, et al. Economisation of vaccination against Haemophilus influenzae type b: a randomised trial of immunogenicity of fractional-dose and two-dose regimens. Lancet 1998; 351: 1472-1476.
34. Mangtani P, et al. Haemophilus influenzae type b disease in HIV-infected children: a review of the disease epidemiology and effectiveness of Hib conjugate vaccines. Vaccine 2010; 28: 1677-1683.
35. Madhi SA, et al. Reduced effectiveness of Haemophilus influenzae type b conjugate vaccine in children with
36. Daza P, et al. The impact of routine infant immunization with Haemophilus influenzae type b conjugate vaccine in Malawi, a country with high human immunodeficiency virus prevalence. Vaccine 2006; 24: 6232-6239.
37. Bennett JV, et al. Haemophilus influenzae type b (Hib) meningitis in the pre-vaccine era: a global review of incidence, age distributions, and case-fatality rates. WHO/V&B/0218. Geneva: WHO, 2002.
38. von Gottberg A CC, et al. Invasive disease due to Haemophilus influenzae serotype b ten years after routine vaccination, South Africa, 2003-2009. Vaccine 2012; 30: 565-71.
39. Ramsay ME, et al. Estimating Haemophilus influenzae type b vaccine effectiveness in England and Wales by use of the screening method. Journal of Infectious Diseases 2003; 188: 481-485.
40. McVernon J, et al. Trends in Haemophilus influenzae type b infections in adults in England and Wales: surveillance study. British Medical Journal 2004; 329: 655-658.
41. Black SB, et al. Efficacy in infancy of oligosaccharide conjugate Haemophilus influenza type b (HbOC) vaccine in a United States population of 61,080 children. The Northern California Kaiser Permanente Vaccine Study Center Pediatrics Group. Pediatric Infectious Disease Journal 1991; 10: 97-104.
42. Booy R, et al. Efficacy of Haemophilus influenzae type b conjugate vaccine PRP-T. Lancet 1994; 344: 362-366.
43. Lagos R, et al. Large scale, postlicensure, selective vaccination of Chilean infants with PRPT conjugate vaccine: Practicality and effectiveness in preventing invasive Haemophilus influenzae type b infections. Pediatric Infectious Disease Journal 1996; 15: 216-222.
44. Levine OS, et al. Defining the burden of pneumonia in children preventable by vaccination against Haemophilus influenzae type b. Pediatric Infectious Disease Journal 1999; 18: 1060-1064.
45. Vadheim C.M. Vadheim C.M. et al. Effectiveness and safety of a haemophilus influenzae type b conjugate vaccine PRPT in young infants Kaiser-UCLA Vaccine Study Group Pediatrics 1993 92 272-279.